Breaking News Instant updates and real-time market news.

BSX

Boston Scientific

$28.31

0.08 (0.28%)

, MDT

Medtronic

$79.57

-0.27 (-0.34%)

04:55
04/14/18
04/14
04:55
04/14/18
04:55

Society of American Gastrointestinal & Endoscopic Surgeons hold annual meeting

SAGES 2018 Annual Meeting and World Congress of Endoscopic Surgery will be held in Seattle, Washington on April 11-14.

BSX

Boston Scientific

$28.31

0.08 (0.28%)

MDT

Medtronic

$79.57

-0.27 (-0.34%)

JNJ

Johnson & Johnson

$130.62

0.19 (0.15%)

SYK

Stryker

$158.35

-0.21 (-0.13%)

ISRG

Intuitive Surgical

$414.63

-0.42 (-0.10%)

DDD

3D Systems

$11.94

-0.05 (-0.42%)

APEN

Apollo Endosurgery

$5.90

0.05 (0.85%)

BAX

Baxter

$65.72

-0.05 (-0.08%)

BDX

Becton Dickinson

$225.37

1.92 (0.86%)

CNMD

CONMED

$61.90

-0.04 (-0.06%)

HYH

Halyard Health

$47.10

-0.21 (-0.44%)

LXRX

Lexicon

$8.09

-0.28 (-3.35%)

MNK

Mallinckrodt

$13.79

-0.1 (-0.72%)

MDXG

MiMedx

$6.97

0.03 (0.43%)

MRK

Merck

$57.17

0.43 (0.76%)

OBLN

Obalon Therapeutics

$3.43

-0.02 (-0.58%)

PCRX

Pacira

$33.45

-1.1 (-3.18%)

SHPG

Shire

$152.19

-5.73 (-3.63%)

SNY

Sanofi

$40.56

-0.37 (-0.90%)

TFX

Teleflex

$257.52

-0.7 (-0.27%)

SNE

Sony

$48.89

-0.25 (-0.51%)

WTKWY

Wolters Kluwer

$53.59

0.055 (0.10%)

  • 14

    Apr

  • 16

    Apr

  • 16

    Apr

  • 17

    Apr

  • 17

    Apr

  • 18

    Apr

  • 18

    Apr

  • 19

    Apr

  • 20

    Apr

  • 20

    Apr

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 27

    Apr

  • 28

    Apr

  • 28

    Apr

  • 01

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 05

    May

  • 07

    May

  • 08

    May

  • 08

    May

  • 14

    May

  • 18

    May

  • 21

    May

  • 22

    May

  • 23

    May

  • 29

    May

  • 05

    Jun

  • 22

    Aug

  • 20

    Oct

  • 23

    Oct

  • 21

    Dec

BSX Boston Scientific
$28.31

0.08 (0.28%)

03/19/18
MSCO
03/19/18
NO CHANGE
Target $33
MSCO
Overweight
Boston Scientific price target raised to $33 from $30 at Morgan Stanley
Morgan Stanley analyst David Lewis raised his price target on Boston Scientific to $33 and kept his Overweight rating, citing the company's outperforming growth profile and balance sheet flexibility. Lewis says the company can sustain a 6%-7% organic expansion with its pipeline and a shift to higher growth end markets, which are ineffectively reflected in valuation. The analyst adds that while the selloff was driven by concerns around Lotus Edge, the product is "more of a call option" based on the company's core performance.
03/22/18
ADAM
03/22/18
NO CHANGE
Target $35
ADAM
Buy
Canaccord remains a buyer of Boston Scientific following NxThera deal
Canaccord analyst Jason Mills said he would remain a buyer of Boston Scientific following the company's announcement that it will buy NxThera, which which has developed treatments for endo-urological conditions like benign prostatic hyperplasia, or BPH. In a research note to investors, Mills said Boston Scientific raises the long-term growth potential of its Urology and Pelvic Health portfolio, ultimately being in position to sell both surgical and MIS BPH therapeutic modalities.Mills, who has a Buy rating and $35 price target on Boston Scientific shares, expects the company to become "increasingly" active in M&A, noting that he likes the company's strategic vision and potential, and is "bullish" about the growth prospects of its core franchises.
03/26/18
WELS
03/26/18
NO CHANGE
WELS
IPR decision a 'nice' win for Edwards Lifesciences, says Wells Fargo
Wells Fargo analyst Lawrence Biegelsen notes USPTO has determined that all claims of the '608 patent that have been asserted against Edwards Lifesciences (EW) are invalid, which the analyst sees as an important victory for the company because the '608 patent is one of Boston Scientific's (BSX) key transcatheter valve patents. While Boston Scientific will appeal the USPTO's decision on the '608 patent, Biegelsen's patent consultant believes the company's chances of overturning the decision are very low.
02/23/18
02/23/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Boston Scientific (BSX) assumed with an Overweight at Piper Jaffray. 2. Motorola Solutions (MSI) resumed with an Outperform at Raymond James. 3. Albemarle (ALB) initiated with a Buy at Argus. 4. New Relic (NEWR) initiated with an Outperform at Wedbush. 5. CTI BioPharma (CTIC) initiated with an Outperform at Oppenheimer. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MDT Medtronic
$79.57

-0.27 (-0.34%)

04/11/18
RILY
04/11/18
INITIATION
Target $26.5
RILY
Buy
Intricon initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva started Intricon (IIN) with a Buy rating and $26.50 price target. The analyst says the company's partnership with Medtronic (MDT) offers steady growth while new legislation is favorable.
03/12/18
PIPR
03/12/18
NO CHANGE
PIPR
Overweight
Medtronic FDA news a 'nice win' for Dexcom in near-term, says Piper Jaffray
Piper Jaffray analyst JP McKim noted that Medtronic's (MDT) Guardian Connect system received FDA approval, but did not receive a non-adjunctive claim, which Dexcom (DXCM) and Abbott's (ABT) Libre have. The Guardian Connect system will not get Medicare coverage because of this, said McKim, who called the news a "nice win" for Dexcom in the near-term. While Kim does see Medtronic's system getting the claim eventually, he does not expect the Guardian Sensor to be a material threat to Dexcom in 2018 on a standalone basis, calling Medtronic a "pump first company." He keeps an Overweight rating on Dexcom shares.
03/16/18
NEED
03/16/18
DOWNGRADE
NEED
Underperform
Mazor Robotics downgraded to Underperform from Hold at Needham
Needham analyst Mike Matson downgraded Mazor Robotics (MZOR) to Underperform from Hold, forecasting a "significant" slowdown in the company's growth this year as well as more intense competition in the robotics space. Matson adds that Mazor's valuation is priced to a "best case scenario" that is unlikely to be achieved while an acquisition by Medtronic (MDT) is also "extremely unlikely".
04/13/18
CANT
04/13/18
NO CHANGE
Target $490
CANT
Overweight
Cantor sees 'several reasons' for Intuitive Surgical's momentum continuing
Cantor Fitzgerald analyst Craig Bijou reiterates an Overweight rating on Intuitive Surgical with a $490 price target after attending the Society of American Gastrointestinal and Endoscopic Surgeons meeting. There were several scientific sessions highlighting Intuitive's robot for a broad range of procedures, Bijou tells investors in a research note. The analyst sees "several reasons" to believe that the company's momentum will continue. He notes that the uncertain timing for Medtronic's (MDT) robot remains positive for Intuitive Surgical.
JNJ Johnson & Johnson
$130.62

0.19 (0.15%)

03/27/18
BMOC
03/27/18
NO CHANGE
Target $13
BMOC
Outperform
Protagonist Therapeutics price target lowered to $13 from $42 at BMO Capital
BMO Capital analyst M. Ian Somaiya slashed his price target on Protagonist Therapeutics (PTGX) to $13 following the announcement that the company is discontinuing its Phase 2b study of PTG-100 in patients with moderate to severe ulcerative colitis. Somaiya adds that his valuation is now driven by the risk-adjusted sales model for PTG-200, which "represents a higher probability clinical program with peak sales of over $2B". The analyst also notes that he continues to exclude the clinical data of PTG-300 from his model. Despite the steep price target revision, Somaiya keeps his Outperform rating and recommends that investors buy into the weakness after the PTG-100 clinical disappointment on anticipated PTG-200 data and the advancement of Johnson&Johnson (JNJ) - shared Stelara.
04/03/18
RBCM
04/03/18
NO CHANGE
Target $155
RBCM
Outperform
Johnson & Johnson Q1 revenue should top consensus, says RBC Capital
RBC Capital analyst Glenn Novarro believes that Johnson & Johnson's revenue for Q1 should exceed consensus estimate thanks to "another strong performance by Pharmaceutical segment", which should generate a "sufficient catalyst for a sentiment reversal among investors" and produce a 2018 recovery in the stock price. Novarro recommends that investors buy into the release of Q1 earnings on April 17th while keeping his Outperform rating and $155 price target on Johnson & Johnson.
03/21/18
MSCO
03/21/18
NO CHANGE
Target $209
MSCO
Equal Weight
Bluebird Bio price target to $209 from $152 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison raised his price target on Bluebird Bio (BLUE) to $209 from $152, stating that he now expects BCMA therapies to take 50% of the third line market by 2030 and noting that bb2121 has 50% market share there. The new assumptions increase his peak sales forecast to about $2.6B from about $1B, he pointed out. However, Harrison keeps an Equal Weight rating on Bluebird, stating that he would expect new data to be available at ASCO in June, but would also expect to see competitor data potentially from Celgene's (CELG) Juno, Gilead's (GILD) Kite, Johnson & Johnson's (JNJ) Nanjing Legend and others.
04/02/18
EVER
04/02/18
INITIATION
Target $165
EVER
In Line
Stryker initiated with an In Line at Evercore ISI
Evercore ISI analyst Vijay Kumar started Stryker (SYK) with an In Line rating and $165 price target, noting that the company has been a net share gainer in most orthopedics end markets, while Johnson & Johnson (JNJ) has been a net share loser across the board.
SYK Stryker
$158.35

-0.21 (-0.13%)

04/03/18
04/03/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. LogMeln (LOGM) initiated with a Buy at Mizuho. 2. Jones Lang LaSalle (JLL) initiated with a Neutral at Goldman Sachs. 3. Spotify (SPOT) initiated with a Buy at Guggenheim. 4. USA Technologies (USAT) initiated with a Buy at Lake Street. 5. Stryker (SYK) initiated with an In Line at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/15/18
RAJA
03/15/18
INITIATION
Target $183
RAJA
Outperform
Stryker initiated with an Outperform at Raymond James
Raymond James analyst Lawrence Keusch started Stryker with an Outperform rating and $183 price target.
02/27/18
02/27/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Stryker (SYK) upgraded to Neutral from Sell at Citi by analyst Amit Hazan, who believes supply issues at Zimmer Biomet (ZBH) could drive share gains for Stryker. 2. Chipotle (CMG) upgraded to Outperform from Neutral at Baird by analyst David Tarantino, who cited its new CEO and the potential for the company to demonstrate better sales/traffic momentum over the next 12-24 months. He believes it will support investor sentiment given the opportunity for the company to deliver strong earnings power if unit volumes begin to recover. 3. Itron (ITRI) upgraded to Buy from Hold at Cannacord Genuity by analyst Chip Moore, who said he has increased conviction in the company's forward earnings power and finds current share levels a "very compelling" entry point. He notes the stock is down 10% since the SilverSpring Networks deal announcement back in September. Moore's views the combination as compelling and has increased confidence in cost saving potential post close. 4. Winnebago (WGO) upgraded to Outperform from Market Perform at BMO Capital by analyst Gerrick Johnson, who said that the RV market growth -- currently in its 9th year -- will continue at a 10% pace, adding that the company's growth can outgain the competition because of its "operating improvement, enhanced product offering, and emerging trade-up cycle from first time buyers." The analyst also noted that Winnebago will benefit from lower corporate taxes while its stock trades at "significant" valuation discount. 5. Exelixis (EXEL) upgraded to Outperform from Perform at Oppenheimer by analyst Leah Rush Cann. The analyst is now applying a valuation methodology for profitable companies to Exelixis, since the company turned profitable for the full-year 2017. She expects Exelixis will continue to develop its commercial drugs, Cabometyx and Cometriq, while its partner Genentech (RHHBY) will continue to develop Cotellic. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ISRG Intuitive Surgical
$414.63

-0.42 (-0.10%)

01/26/18
STFL
01/26/18
NO CHANGE
Target $480
STFL
Buy
Intuitive Surgical price target raised to $480 from $400 at Stifel
Stifel analyst Rick Wise noted that Intuitive Surgical management reiterated its previously provided 2018 procedure growth outlook for 11%-15% growth, but he points out that over the last several years initial procedure growth guidance has ultimately proved to be conservative. While he thinks the shares may experience some transient softness following the quarterly report and guidance, he would be a buyer on weakness. Wise raised his price target on Intuitive Surgical shares to $480 and keeps a Buy rating on the stock.
01/26/18
RBCM
01/26/18
NO CHANGE
Target $430
RBCM
Sector Perform
Intuitive Surgical price target raised to $430 from $350 at RBC Capital
RBC Capital analyst Brandon Henry raised his price target on Intuitive Surgical to $430 and kept his Sector Perform rating after Q4 earnings. Henry says the company has continued to spend aggressively to accelerate development on several pipeline technologies that will expand its total addressable market and allow the company to remain a premium player in the surgical robotics market despite the increasing competition.
02/07/18
PIPR
02/07/18
NO CHANGE
Target $405
PIPR
Neutral
Piper sees limited competition for Intuitive Surgical over next two years
After digging into many of the companies developing a soft tissue surgical system that may be viewed as competitive to Intuitive Surgical's da Vinci family, Piper Jaffray analyst Matt O'Brien does not believe any of the new systems will meaningfully impact Intuitive Surgical's ability to place robots or perform cases in 2018 or 2019. The analyst says he would not be surprised to see a bit of pricing pressure materialize on Intuitive starting in 2019 and have more impact in 2020, which he believes "could impact results somewhat." O'Brien expects volatility around the stock as the approval/expanded indications occur, but he doubts the news will "severely derail the name in the near term." The analyst keeps a Neutral rating on Intuitive Surgical with a $405 price target.
DDD 3D Systems
$11.94

-0.05 (-0.42%)

03/15/18
NEED
03/15/18
NO CHANGE
NEED
Hold
3D Systems Q4 earnings driven by Services, says Needham
Needham analyst James Ricchiuti writes that the Q4 earnings beat for 3D systems was driven by Services, particularly Healthcare, while Printer unit revenues continued to lag. Ricchiuti adds that the company has "several new products" launching this year, but a boost to its hardware system may still be several quarters away. The analyst keeps his Hold rating on 3D Systems.
02/09/18
JPMS
02/09/18
DOWNGRADE
Target $11
JPMS
Underweight
JPMorgan downgrades 3D Systems to Underweight after 14% year-to-date rally
JPMorgan analyst Paul Coster downgraded 3D Systems to Underweight from Neutral with the shares up 14% year-to-date. The current multiple prices in a return to growth that will prove premature, Coster tells investors in a research note. He expects 3D Systems will underperform the mean of his coverage over the next 6-12 months, but does not view the stock as a good short. The analyst keeps an $11 price target on the shares. 3D Systems closed yesterday down 50c to $9.82.
02/09/18
JPMS
02/09/18
DOWNGRADE
Target $11
JPMS
Underweight
3D Systems downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Paul Coster downgraded 3D Systems to Underweight with an $11 price target.
11/20/17
11/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Verizon (VZ) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jennifer Fritzsche saying after dropping 16% since mid-January, "much of the bad news is behind the stock" in terms of wireless service revenue declines. 2. 3D Systems (DDD) upgraded to Neutral from Underweight at Piper Jaffray with analyst Troy Jensen saying he sees limited downside from current share levels. 3. Viacom (VIAB, VIA) upgraded to Hold from Sell at Deutsche Bank with analyst Bryan Kraft saying he sees limited room for further multiple compression. 4. Maxwell (MXWL) upgraded to Buy from Neutral at Roth Capital with analyst Craig Irwin saying he sees consensus estimates as achievable for 2018, and merger synergies with NessCap should start making a more material contribution over the next few quarters. 5. National Beverage (FIZZ) upgraded to Positive from Neutral at Susquehanna with analyst Pablo Zuanic citing his increased conviction on the sales and bottom-line upside of the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
APEN Apollo Endosurgery
$5.90

0.05 (0.85%)

04/13/18
PIPR
04/13/18
INITIATION
Target $8
PIPR
Overweight
Apollo Endosurgery initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Matt O'Brien started Apollo Endosurgery with an Overweight rating and $8 price target. The company has "turned the corner from a revenue perspective" as a number of key new products should lead to accelerating growth, O'Brien tells investors in a research note. He notes the stock trades at a "meaningful discount" to its peers.
08/11/17
CHLM
08/11/17
NO CHANGE
Target $11
CHLM
Buy
Apollo Endosurgery selloff on FDA letter a buying opportunity, says Craig-Hallum
Craig-Hallum analyst Matt Hewitt said he does not believe the FDA "update" letter regarding potential risks with liquid-filled intragastric balloons will have an adverse impact on future utilization of Apollo Endosurgery's Orbera device and he thinks the selloff related to its publication presents an opportunity for investors. Hewitt keeps a Buy rating and $11 price target on Apollo Endosurgery shares.
09/26/17
NORL
09/26/17
INITIATION
Target $12
NORL
Outperform
Apollo Endosurgery initiated with an Outperform at Northland
Northland initiated Apollo Endosurgery with an Outperform and $12 price target.
01/04/18
ROTH
01/04/18
INITIATION
Target $9.5
ROTH
Buy
Apollo Endosurgery resumed with a Buy at Roth Capital
Roth Capital analyst Scott Henry resumed coverage of Apollo Endosurgery with a Buy rating and $9.50 price target on the potential to "unmask" top-line growth near-term and experience sustained long-term growth through its Endo-Bariatric segment that offers minimally invasive solutions to the obesity epidemic.
BAX Baxter
$65.72

-0.05 (-0.08%)

02/02/18
COWN
02/02/18
NO CHANGE
Target $78
COWN
Market Perform
Baxter guidance reaction unwarranted, says Cowen
Cowen analyst Joshua Jennings noted Baxter's Q2 guidance implied a headwind to operating margins and the shares sold off. The analyst believes the selloff was an overreaction and unwarranted, though, as he believes the guidance could be conservative and it will not disrupt the company's multiyear margin progress. Jennings maintained his Market Perform rating and raised his price target to $78 from $68 on Baxter shares.
01/03/18
RAJA
01/03/18
UPGRADE
Target $73
RAJA
Outperform
Baxter upgraded to Outperform, view as a core holding at Raymond James
Raymond James analyst Lawrence Keusch upgraded Baxter to Outperform from Market Perform and established a $73 price target saying he views it as a core holding. Keusch has high confidence in management execution, an emerging new product portfolio, and balance sheet optionality. He sees organic cc revenue growth in the 4% range driven by geographic expansion after recent underperformance in Europe, as well as continued growth in Asia. Further, after a period of underinvestment, the R&D pipeline as been revitalized and should begin to accelerate growth in 2019 and beyond. Finally, the analyst said Baxter has considerable balance sheet flexibility with $7-$8B available for bolt-on acquisitions.
01/03/18
EVER
01/03/18
INITIATION
Target $71
EVER
Outperform
Baxter initiated with an Outperform at Evercore ISI
Evercore ISI analyst Vijay Kumar started Baxter with an Outperform rating and $71 price target. The analyst thinks Baxter should be able to meet or beat 2018 Street expectations and its balance sheet strength gives it over $10B in capacity for M&A, he tells investors.
02/20/18
DBAB
02/20/18
UPGRADE
Target $80
DBAB
Buy
Baxter upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Kristen Stewart upgraded Baxter International to Buy and raised her price target for the shares to $80 from $50. The analyst expects management to execute well and she views the company's 2018 guidance as achievable, if not conservative. She sees the May analyst day as an upcoming catalyst and believes the stock deserves a premium valuation.
BDX Becton Dickinson
$225.37

1.92 (0.86%)

04/10/18
04/10/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ulta Beauty (ULTA) upgraded to Overweight from Neutral at Piper Jaffray with analyst Erinn Murphy citing Piper's 35th semi-annual teens survey in which Ulta Beauty overtook Sephora as the top brand for average-income teens. 2. Nvidia (NVDA) and Seagate (STX) were upgraded to Overweight from Equal Weight at Morgan Stanley. 3. Live Nation (LYV) upgraded to Buy from Neutral at Citi with analyst Jason Bazinet saying the stock has sold off after the New York Times reported that the Department of Justice is investigating the company for antitrust violations. 4. Becton Dickinson (BDX) upgraded to Buy from Neutral at Citi with analyst Amit Hazan saying he sees a "strong setup" for upside to estimates in fiscal 2018, largely driven by the Becton Dickinson side of the business. 5. Illinois Tool Works (ITW) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Joe Ritchie saying the pullback in shares due to auto concerns provides an attractive entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/18
SBSH
04/10/18
UPGRADE
Target $251
SBSH
Buy
Becton Dickinson upgraded to Buy from Neutral at Citi
Citi analyst Amit Hazan upgraded Becton Dickinson to Buy and raised his price target for the shares to $251 from $237. The analyst sees a "strong setup" for upside to estimates in fiscal 2018, largely driven by the Becton Dickinson side of the business. Further, he sees drug-coated balloons as an important growth driver for the Bard side of the business.
03/05/18
BMOC
03/05/18
INITIATION
Target $249
BMOC
Market Perform
Becton Dickinson initiated with a Market Perform at BMO Capital
BMO Capital analyst Joanne Wuensch initiated Becton Dickinson with a Market Perform rating and a $249.00 price target.
03/06/18
03/06/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Becton Dickinson (BDX) initiated with a Market Perform at BMO Capital. 2. Cardlytics (CDLX) initiated with a Buy at SunTrust, an Overweight at JPMorgan and KeyBanc, a Neutral at BofA/Merrill, and an Outperform at Wells Fargo. 3. iRhythm (IRTC) initiated with an Outperform at BMO Capital. 4. Genocea (GNCA) initiated with an Overweight at Cantor Fitzgerald. 5. Domino's Pizza (DPZ) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CNMD CONMED
$61.90

-0.04 (-0.06%)

02/13/18
NEED
02/13/18
NO CHANGE
NEED
Needham a buyer of Medical Technologies product makers on Amazon headlines
After The Wall Street Journal report claiming that Amazon (AMZN) is attempting to become a major hospital supplier, Needham analyst Mike Matson said that he believes the e-commerce giant has typically disrupted middlemen much more than manufacturers. The analyst, who thinks Amazon's model may work for "lower tech" products but is unlikely to work with "higher tech" products, would be a buyer of Medical Technologies product maker stocks if they are down on weakness related to the headline risk represented by Amazon. However, Matson notes that he believe that Cantel Medical (CMD), CONMED (CNMD), Medtronic (MDT), Stryker (SYK) and Teleflex (TFX) generate a portion of their sales from "lower tech" products. Other stocks in MedTech manufacturing include AtriCure (ATRI), Cardiovascular Systems (CSII), Hill-Rom (HRC), K2M Group (KTWO), Mazor Robotics (MZOR), Zimmer Biomet (ZBH), Boston Scientific (BSX), Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI).
02/01/18
NEED
02/01/18
NO CHANGE
Target $71
NEED
Buy
CONMED price target raised to $71 from $58 at Needham
Needham analyst Mike Matson raised his price target on CONMED to $71 and kept his Buy rating after Q4 earnings beat. The analyst says the company has "finally turned around its US Orthopedics business which was the one remaining drag on its growth". Matson also cites the management's forecast of sustaining mid-single digit revenue growth and double-digit EPS growth, which he adds may prove to be conservative.
04/27/17
LEER
04/27/17
NO CHANGE
Target $52
LEER
Market Perform
CONMED price target raised to $52 from $45 at Leerink
Leerink analyst Richard Newitter raised his price target for CONMED to $52 from $45 after the company delivered a "good Q1" with revenue/EPS ahead of expectations. The analyst reiterates a Market Perform rating on the shares.
04/27/17
NEED
04/27/17
NO CHANGE
Target $54
NEED
Buy
CONMED price target raised to $54 from $48 at Needham
Needham analyst Mike Matson raised his price target for CONMED to $54 from $48 after the company's Q1 revenue and EPS beat consensus and management maintained its 2017 guidance. The analyst is encouraged by the improvement in revenue growth and reiterates a Buy rating, though he needs to see it sustained for a few more quarters before he is comfortable declaring the CONMED turnaround a success.
HYH Halyard Health
$47.10

-0.21 (-0.44%)

04/06/18
KEYB
04/06/18
UPGRADE
Target $61
KEYB
Overweight
Halyard Health upgraded to Overweight with $61 price target at KeyBanc
KeyBanc analyst Matthew Mishan last night upgraded Halyard Health to Overweight from Sector Weight with a $61 price target. The analyst sees the company's earnings growth accelerating and valuation re-rating following the sale of its Surgical & Infection Prevention unit. After hosting investor meetings with management, Mishan believes accelerated multiyear earnings growth could sustain a higher valuation for Halyard.
08/03/17
08/03/17
UPGRADE
Target $47

Overweight
Halyard Health upgraded to Overweight at Stephens
As previously reported, Stephens analyst Chris Cooley upgraded Halyard Health to Overweight from Equal Weight following the company's Q2 report and increase to 2017 non-GAAP earnings guidance. Additionally, the analyst believes a heightened focus on M&A may serve to further bolster the underlying growth and margin profile longer-term. Cooley also raised his price target on the shares to $47 from $40.
04/06/18
04/06/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Valeant (VRX) upgraded to Neutral from Underperform at Mizuho with analyst Irina Koffler saying while she remains concerned about Valeant's return to revenue growth, sees no near-term "sell catalysts." 2. Patterson Companies (PDCO) upgraded to Buy from Hold at Craig-Hallum with analyst Kevin Ellich saying that his sum-of-parts analysis suggests the company could unlock value by splitting its dental and animal health businesses. 3. Prologis (PLD) and AvalonBay (AVB) were upgraded to Buy from Neutral at Citi. 4. Universal Display (OLED) upgraded to Outperform from Perform at Oppenheimer with analyst Andrew Uerkwitz saying with the shares down 41% year-to-date, the stock is oversold and the risks are fully priced in. 5. Halyard Health (HYH) upgraded to Overweight from Sector Weight at KeyBanc with analyst Matthew Mishan saying he sees the company's earnings growth accelerating and valuation re-rating following the sale of its Surgical & Infection Prevention unit. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/05/18
KEYB
04/05/18
UPGRADE
KEYB
Overweight
Halyard Health upgraded to Overweight from Sector Weight at KeyBanc
LXRX Lexicon
$8.09

-0.28 (-3.35%)

02/14/18
JPMS
02/14/18
DOWNGRADE
Target $10
JPMS
Underweight
Lexicon downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Jessica Fye downgraded Lexicon Pharmaceuticals to Underweight and lowered her price target for the shares to $10 from $15. The Xermelo launch remains slow, and consensus estimates of $55M and $99M for 2018 and 2019 are too high, Fye tells investors in a research note. The analyst sees more risks for the stock to underperform with limited catalysts in the year to drive meaningful upside beyond an "outright competitor stumble" in type 1 diabetes.
02/23/18
NEED
02/23/18
DOWNGRADE
NEED
Hold
Lexicon downgraded to Hold at Needham
As reported earlier, Needham analyst Alan Carr downgraded Lexicon Pharma to Hold from Buy after the company's U.S. Xermelo sales came in below expectations. Carr cites the ongoing challenges that include "low number of patient starts and a large number of Medicare patients receiving free drug under a company assistance program". While the company believes that patient starts are rebounding, the analyst contends that Xermelo launch trajectory implies a more modest peak in sales.
02/23/18
NEED
02/23/18
DOWNGRADE
NEED
Hold
Lexicon downgraded to Hold from Buy at Needham
02/14/18
02/14/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PepsiCo (PEP) downgraded to In Line from Outperform at Evercore ISI with analyst Robert Ottenstein saying that while the company's dividend increase is "important and positive," he no longer expects the company to outperform in the beverage sector amid an "array of issues" at North America Beverage segment limiting upside performance. 2. Spark Therapeutics (ONCE) downgraded to Neutral from Overweight at JPMorgan with analyst Cory Kasimov saying he remains optimistic about the long-term outlook for the company, but notes the shares are now within 10% of his price target following the recent rally. 3. Chimerix (CMRX) downgraded to Underweight from Neutral at JPMorgan with analyst Jessica Fye saying with base-case timing for the AdAPT data well over a year away, the shares will underperform over the near term. 4. Avis Budget (CAR) downgraded to Sell from Neutral at Goldman Sachs with analyst David Tamberrino saying he believes transitory benefits from Hurricane recovery demand are waning, and headwinds from reduced residual values, higher interest rates, continued competition, and increased SG&A expenses will pressure Avis' earnings outlook. 5. Lexicon (LXRX) downgraded to Underweight from Neutral at JPMorgan with analyst Jessica Fye saying the Xermelo launch remains slow, and consensus estimates of $55M and $99M for 2018 and 2019 are too high. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MNK Mallinckrodt
$13.79

-0.1 (-0.72%)

04/12/18
04/12/18
DOWNGRADE
Target $15

Hold
Stifel downgrades Mallinckrodt to Hold with sentiment seen staying low
As previously reported, Stifel analyst Annabel Samimy downgraded Mallinckrodt to Hold from Buy. Samimy said he cannot prove or disprove the alleged improper Acthar distribution and Medicare claims made against Mallinckrodt in a recently filed whistleblower lawsuit, but he believes that the "singularly persistent" overhang of Acthar will not lift in the near-term, regardless of the strength of the company's upcoming pipeline opportunities. The analyst thinks it is prudent to step to the side until the Acthar overhang, coupled with the overhang of opioid litigation, has more clarity toward resolution, he tells investors. Samimy lowered his price target on Mallinckrodt shares to $15 from $50.
04/12/18
STFL
04/12/18
DOWNGRADE
STFL
Hold
Mallinckrodt downgraded to Hold from Buy at Stifel
04/12/18
WELS
04/12/18
NO CHANGE
WELS
Market Perform
Wells says suit against Salix may have been filed by Mallinckrodt whistleblower
Wells Fargo analyst David Maris said he found reference to a lawsuit filed by a Rasivinder Dhaliwal against Salix Pharmaceuticals in January 2015, thought he has not been able to confirm that this Rasivinder Dhaliwal is the same one who filed a recent whistleblower lawsuit against Mallinckrodt (MNK). Maris previously stated in a note to investors earlier today that Mallinckrodt strongly disagrees with the allegations, believes the suit is baseless, and plans to defend itself vigorously. The Fly notes that Valeant (VRX) acquired Salix in 2015.
04/12/18
WELS
04/12/18
NO CHANGE
WELS
Market Perform
Mallinckrodt strongly disagrees with whistleblower suit, says Wells Fargo
Mallinckrodt shares are down sharply after news of a whistleblower lawsuit was made public, Wells Fargo analyst David Maris tells investors in an intraday research note. Mallinckrodt strongly disagrees with the allegations, believes the suit is baseless, and plans to defend itself vigorously, Maris writes after speaking to the company. The analyst believes whistleblower suits and court documents "often read poorly for a company as they are often one sided." However, the complaint alleges a number of bad actions by Mallinckrodt that could have larger implications if true, Maris adds. He recommends not jumping to conclusions and keeps a Market Perform rating on Mallinckrodt. The stock in morning trading is down 7% to $13.84.
MDXG MiMedx
$6.97

0.03 (0.43%)

02/27/18
CHLM
02/27/18
NO CHANGE
Target $19
CHLM
Buy
Craig-Hallum maintains Buy rating, $19 price target on MiMedx
Craig-Hallum analyst Matt Hewitt noted that MiMedx denied a report that it is under investigation by the Department of Justice, stating that it is not aware of any such investigation. While stating that "it is impossible to know for certain whether any nefarious activity has ever taken place at MiMedx," Hewitt points to several events over the past year that give him confidence in the integrity of the company's financials. If the company's financials are sound, he estimate that the stock is worth two and a half times the current price, added Hewitt, who keeps a Buy rating and $19 price target on MiMedx shares.
02/23/18
02/23/18
DOWNGRADE
Target $9

Hold
MiMedx downgraded to Hold with $9 price target at Lake Street
As previously reported, Lake Street analyst Bruce Jackson downgraded MiMedx to Hold from Buy, stating that a resolution of the investigation into current and prior period sales and distribution practices is unlikely to be swift and the shares are unlikely to outperform until the investigation is resolved. If the investigation resolves favorably, the upside potential "would be significant and he would be an aggressive buyer of the stock, but for now Jackson cut his price target on MiMedx shares to $9 from $12.
02/23/18
LSCM
02/23/18
DOWNGRADE
LSCM
Hold
MiMedx downgraded to Hold from Buy at Lake Street
03/15/18
PIPR
03/15/18
NO CHANGE
PIPR
Piper suspends MiMedx rating, says DOJ review too much to digest
Piper Jaffray analyst Matt O'Brien suspended his rating and price target on MiMedx Group after the company disclosed that the Department of Justice is reviewing matters in parallel with an SEC investigation. The analyst, up until tonight, had an Overweight rating on MiMedx with an $18 price target. The stock closed the trading day down 15c to $7.12. "We have been standing by MiMedx in recent months despite numerous short selling reports on the company," O'Brien tells investors in a research note. He says, however, that the Department of Justice review, which is added to an Audit Committee and SEC investigation regarding the company's sales and distribution practices, is "simply too much for us to digest at the moment."
MRK Merck
$57.17

0.43 (0.76%)

04/09/18
JEFF
04/09/18
DOWNGRADE
Target $4
JEFF
Hold
NewLink Genetics downgraded to Hold with $4 target at Jefferies
Jefferies analyst Biren Amin late Friday downgraded NewLink Genetics (NLNK) to Hold from Buy and cut his price target for the shares to $4 from $17. The stock closed Friday down 43%, or $3.12, to $4.20. The analyst does not see a scenario in which the company's IDO inhibitor can avoid the same fate as Incyte and Merck's epacadostat plus Keytruda failed study.
04/09/18
OPCO
04/09/18
NO CHANGE
Target $65
OPCO
Perform
Incyte price target lowered to $65 from $110 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Incyte (INCY) to $65 from $110 following the update on the termination of ECHO-301 after epacadostat failed to show a PFS or OS benefit when combined with Merck's (MRK) Keytruda versus Keytruda alone. While the company plans to conduct subgroup analyses of ECHO-301 looking at various biomarkers such as PD-L1 expression and tumor mutational burden which may provide additional insights, the analyst sees no reason at this time to continue development of epacadostat as he considers it highly unlikely to demonstrate efficacy in other tumor types and/or combinations. Olson reiterates a Perform rating on Incyte's shares.
04/09/18
HCWC
04/09/18
NO CHANGE
Target $125
HCWC
Buy
Nektar data 'more robust' than Incyte's, says H.C. Wainwright
The failure of Incyte (INCY) and Merck's (MRK) Phase 3 study negatively impacted trading in Nektar Therapeutics (NKTR) shares on Friday, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note titled "Collateral Damage Not Surprising; Expecting ASCO-18 to Validate the Master T Cell Regulator Hypothesis." At this year's American Society of Clinical Oncology meeting, the analyst expects Nektar and partner Bristol-Myers Squibb (BMY) to unveil data from at least 40 advanced melanoma patients "supported by in-depth biomarker characterization to comprehensively ascertain the rationale of combining NKTR-214 with Opdivo." The rationale for combining NKTR-214 with Opdivo is "more robust" than epacadostat plus Keytruda, the analyst contends. Further, he believes data generated by the NKTR-214 plus Opdivo combination is "unambiguous." Chattopadhyay reiterates a Buy rating on Nektar shares with a $125 price target.
04/12/18
SBSH
04/12/18
NO CHANGE
SBSH
Sell
Pfizer has no interest in acquiring Bristol-Myers right now, says Citi
Citi analyst Andrew Baum says Pfizer's (PFE) CEO made it clear to him that the company has no interest in acquiring Bristol-Myers Squibb (BMY) in the absence of transformational data or a de-rating in the shares. Pfizer has high conviction in its current pipeline and believes that the return on investment is considerably higher than high risk transformational deals, particularly in the immuno-oncology space, Baum tells investors in a research note. The analyst expects Pfizer will meaningfully increase its current share repurchase program from the current $5B-$6B per annum to offset the earnings dilution from higher anticipated R&D investment to monetize its current pipeline. Baum keeps a Sell rating on Pfizer and continues to prefer shares of Merck (MRK), Bristol and Eli Lilly (LLY) in the U.S. The analyst lowered his price target for Bristol shares to $70 from $78 with Pfizer backing away from a potential takeover. He keeps a Buy rating on the shares, however.
OBLN Obalon Therapeutics
$3.43

-0.02 (-0.58%)

06/21/17
06/21/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Camping World (CWH) initiated with an Outperform at BMO Capital. 2. LendingTree (TREE) initiated with an Outperform at William Blair. 3. DST Systems (DST) initiated with a Buy at DA Davidson. 4. Obalon Therapeutics (OBLN) initiated with an Underperform at Northland. 5. First Defiance Financial (FDEF) initiated with a Hold at Sandler ONeill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/22/18
ADAM
01/22/18
NO CHANGE
Target $11
ADAM
Buy
Obalon Therapeutics price target lowered to $11 from $15 at Canaccord
Canaccord analyst Kyle Rose lowered his price target on Obalon Therapeutics to $11 from $15 to reflect the effects of its follow-on offering. Rose maintains his Buy rating on Obalon Therapeutics given commercial momentum in the underlying business and the positive risk/reward he sees at its current valuation.
01/25/18
NORL
01/25/18
UPGRADE
NORL
Market Perform
Obalon Therapeutics upgraded to Market Perform from Underperform at Northland
03/06/18
BTIG
03/06/18
NO CHANGE
Target $7
BTIG
Buy
Obalon Therapeutics price target lowered to $7 from $12 at BTIG
BTIG analyst Sean Lavin lowered his price target on Obalon Therapeutics to $7 after the company's Q4 earnings. The analyst adds that while the results were in-line with the preannounced figures, which is positive for the company, the conservative guidance is surprising reflecting some weak sentiment. Lavin keeps his Buy rating on Obalon, cheering a more detailed disclosure of commercial metrics but remaining concerned with lack of detail on the company's sales strategy.
PCRX Pacira
$33.45

-1.1 (-3.18%)

04/09/18
HCWC
04/09/18
NO CHANGE
Target $48
HCWC
Buy
Pacira price target raised to $48 from $45 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat raised his price target for Pacira Pharmaceuticals to $48 after the FDA approved an additional "narrow" nerve block indication for Exparel. The FDA added a specific interscalene brachial plexus block indication for regional anesthesia, effectively an indication for shoulder replacement or rotator cuff repair, Livnat tells investors in a research note. While a broad general nerve block indication would have been best case, and Pacira has to be careful not to promote off-label, this is still an "important positive," the analyst contends. He reiterates a Buy rating on Pacira shares.
04/09/18
BMOC
04/09/18
NO CHANGE
Target $34
BMOC
Market Perform
Pacira price target raised to $34 at BMO Capital after Exparel approval
BMO Capital analyst Gary Nachman raised his price target on Pacira to $34 from $31, citing Friday's announcement of FDA approval of an upper extremity nerve block indication for Exparel on the PDUFA. Nachman says this was a "surprising outcome" given a negative panel decision in February, but adds that the indication is also narrow in that it is "limited to an intrascalene brachial plexus block". The analyst keeps his Market Perform rating on Pacira, stating that while Exparel is a " solid product for post-surgical pain, further penetration is challenging and consensus expectations remain high".
04/10/18
MZHO
04/10/18
NO CHANGE
Target $35
MZHO
Buy
Pacira label changes positive for Heron, says Mizuho
Mizuho analyst Difei Yang views FDA approval of Pacira Pharmaceuticals (PCRX) Exparel in nerve block as positive for Heron Therapeutics' (HRTX) HTX-011. The FDA updated the label information of Exparel to include detail on the opioid sparing properties of the drug, which appear "modest and potentially not clinically meaningful," Yang tells investors in a research note. This is in contrast to HTX-011, which has demonstrated "superior opioid sparing properties" in a number of studies including the latest Phase 3 trials, the analyst contends. Yang keeps a Buy rating on Heron with a $35 price target.
04/12/18
COWN
04/12/18
NO CHANGE
COWN
Draft bill could be good for Heron, seems to exclude Pacira drug, says Cowen
Cowen analyst Boris Peaker said a draft bill creating a pass-through payment for non-opioid analgesics as part of surgical procedures appears to exclude Pacira's (PCRX) Exparel, but could benefit Heron Therapeutics' (HRTX) HTX-011. He also noted, though, that several bills would promote the use of local anesthetics. The House E&C committee is planning to move into more formal legislative drafting mode with the goal of reporting legislation out before Memorial Day, Peaker added.
SHPG Shire
$152.19

-5.73 (-3.63%)

02/22/18
BOFA
02/22/18
NO CHANGE
BOFA
Buy
Shire post results weakness overdone, says BofA/Merrill
BofA/Merrill analyst Graham Parry believes Shire post results weakness is overdone and says shares remain undervalued. The analyst argued that cons EPS cuts are already priced in, and reiterates a Buy rating on the shares.
03/28/18
BOFA
03/28/18
NO CHANGE
BOFA
Buy
Still considerable value in Shire even in no Takeda bid scenario, says BofA/Merrill
BofA/Merrill analyst Graham Parry notes that Takeda (TKPYY) has said in a statement that it is considering an approach for Shire (SHPG) but that the consideration is at a preliminary and exploratory stage and no approach has been made to the board of Shire. The analyst continues to see considerable value in Shire with concerns over hemophilia more than priced into the stock and upsides from pipeline, notably SHP643 for HAE and SHP647 for Ulcerative colitis and Crohns, and the value of its plasma/immunology franchise overlooked. Even in a no bid scenario, Parry believes passage through hemophilia overhangs and increased awareness of the value in these assets should see Shire trade higher on 12-month view. He reiterates a Buy rating on Shire's shares.
03/29/18
JEFF
03/29/18
NO CHANGE
Target $172
JEFF
Buy
Shire investors may be amenable to $50B-plus bid, says Jefferies
With challenges in the hemophilia market near term, Shire (SHPG) investors could be amenable to another $50B-plus bid, similar to AbbVie's (ABBV) 2014 offer, Jefferies analyst David Steinberg tells investors in a research note. This would represent a 35% premium to Shire's recent near five-year low valuation, the analyst writes. He says "it remains to be seen" how Takeda Pharmaceutical (TKPYY) could structure a transaction for Shire given the companies' similar equity valuations. The analyst finds it possible that Takeda's disclosed interest could spark competitive bids from large cap pharma companies. He keeps a Buy rating on Shire with a $172 price target.
03/07/18
HCWC
03/07/18
NO CHANGE
Target $12
HCWC
Buy
Caladrius price target raised to $12 from $7 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Caladrius Biosciences (CLBS) to $12 after the company acquired from Shire (SHPG) an exclusive worldwide license to data and regulatory filings for a late-stage CD34+ cell therapy program for the treatment of chronic myocardial ischemia targeting refractory angina. The deal "significantly enriches" Caladrius' existing pipeline and should provide an "additional attractive shot on goal" in the coming years, Selvaraju tells investors in a research note. He increased his valuation of the company to $120M from $60M and reiterates a Buy rating on the shares.
SNY Sanofi
$40.56

-0.37 (-0.90%)

03/12/18
PIPR
03/12/18
NO CHANGE
Target $182
PIPR
Overweight
Piper says Sanofi decision not to op-in on lumasiran positve for Alnylam
Piper Jaffray analyst Edward Tenthoff said he views Sanofi's (SNY) decision not to opt-in for global rights on lumasiran for the treatment of Primary Hyperoxaluria Type 1, or PH1, as a positive for Alnylam (ALNY), as he believes lumasiran could represent a fourth RNAi therapy with potential approval by 2020. Tenthoff, who said he is confident in FDA approval of patisiran by the August 11 PDUFA date and expects givosiran approval in 2019, keeps an Overweight rating and $182 target on Alnylam shares.
02/19/18
JEFF
02/19/18
NO CHANGE
Target $145
JEFF
Buy
AnaptysBio price target raised to $145 from $101 at Jefferies
Jefferies analyst Biren Amin raised his price target for AnaptysBio (ANAB) to $145 after the company presented final data from its Phase IIa trial of ANB020 in 12 mod-to-severe adult atopic dermatitis patients. The shares closed Friday up $6.59, of 5.5%, to $126.45. Sustained efficacy on a single dose of '020 was seen up to day 78 at EASI-50 in 75% of patients, comparable to Phase II data from Sanofi (SNY) and Regeneron (REGN) competitor Dupixent, Amin tells investors in a research note. ANB020 beats if you account for single dose versus Q2 weeks of Dupi, the analyst contends. He keeps a Buy rating on AnaptysBio.
02/26/18
LEER
02/26/18
NO CHANGE
LEER
Leerink remains positive on Regeneron/Sanofi Dupixent
Leerink analyst Geoffrey Porges says sentiment about the revenue potential of Regeneron (REGN)/Sanofi's (SNY) Dupixent has been declining over the past year, despite an impressive launch, and a steady flow of data for new indications and populations. The analyst remains positive about the product, forecasting 2020 revenue of $4B and growing to $6.5B by 2022 and $7.8B by 2025 from multiple indications.
03/12/18
RILY
03/12/18
NO CHANGE
Target $200
RILY
Buy
Alnylam bear argument undercut by Regeneron data, says B. Riley FBR
B. Riley FBR analyst Madhu Kumar believes this weekend's Odyssey Outcomes data from Regeneron (REGN) and Sanofi (SNY) undercuts the bear argument on Alnylam Pharmaceuticals (ALNY) that PCSK9 drugs do not demonstrate clinically meaningful mortality benefit. Further, the analyst believes Sanofi and Regeneron's lower Praluent pricing in high-risk patients will likely expand uptake of PCSK9 drugs in the cholesterol market. Kumar keeps a Buy rating on Alnylam with a $200 price target.
TFX Teleflex
$257.52

-0.7 (-0.27%)

02/23/18
LEER
02/23/18
NO CHANGE
Target $300
LEER
Outperform
Teleflex selloff presents buying opportunity, says at Leerink
Leerink analyst Richard Newitter lowered his price target for Teleflex to $300 from $321 but believes the 8% post-earnings selloff in the stock presents a buying opportunity. The analyst is giving management the benefit of the doubt that the main culprits behind weak Q4 organic revenue growth should prove transient. He believes the stock's premium valuation is justified and reiterates an Outperform rating on the name.
04/04/18
GSCO
04/04/18
INITIATION
Target $257
GSCO
Neutral
Teleflex initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Issac Ro started Teleflex with a Neutral rating and $257 price target.
03/02/18
PIPR
03/02/18
NO CHANGE
Target $295
PIPR
Overweight
Teleflex recent pullback overdone, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien views the recent pullback in shares of Teleflex as overdone. The issues that affected Q4 "are indeed transitory and will reverse soon," O'Brien tells investors in a research note after hosting meetings with management. The analyst notes the company's optimism for Neotract has not waned. He believes the franchise will be a "meaningful growth driver (potentially above the 40% guidance rate) for many years to come." O'Brien recommends taking advantage of the recent selloff in Teleflex shares and keeps an Overweight rating on the name with a $295 price target.
SNE Sony
$48.89

-0.25 (-0.51%)

01/23/18
01/23/18
DOWNGRADE

Neutral
Sony downgraded to Neutral on slowing dual-cam adoption at JPMorgan
As previously reported, JPMorgan downgraded Sony (SNE) to Neutral from Overweight, citing slowing adoption of dual-cams. The firm notes that reports indicate Apple's (AAPL) iPhone 6.05" LCD model will not have a dual-cam feature, which it sees presenting a material downside risk in dual-camera adoption in the second half of 2018.
01/23/18
JPMS
01/23/18
DOWNGRADE
JPMS
Neutral
Sony downgraded to Neutral from Overweight at JPMorgan
11/17/17
RILY
11/17/17
NO CHANGE
Target $36
RILY
Neutral
21st Century Fox price target raised to $36 from $29 at B. Riley FBR
B. Riley FBR analyst Barton Crockett raised his price target for 21st Century Fox (FOXA) to $36 citing recent reports that Disney (DIS), Comcast (CMCSA), Verizon (VZ) or Sony (SNE) may make offers for the company. The "formerly unthinkable" prospect of Rupert Murdoch selling assets is likely to be factored into the equity price for some time, Crockett tells investors in a research. He keeps a Neutral rating on Fox given the stock's proximity to his new target.
12/07/17
BARD
12/07/17
NO CHANGE
BARD
Data so far suggesting healthy holiday game sales, says Baird
Baird analyst Colin Sebastian noted that French game maker Ubisoft (UBSFY) raised its revenue and margin guidance for the December quarter, which he views as a slight positive for video game industry sales momentum this holiday season. Data also point to solid sales for both Sony's (SNE) PS4 and Nintendo's (NTDOY) Switch, which are a driver of software as well as a key catalyst for Gamestop (GME), Sebastian added. Other publicly traded companies in the video game space include Activision Blizzard (ATVI), Electronic Arts (EA), Take-Two (TTWO) and Microsoft (MSFT).
WTKWY Wolters Kluwer
$53.59

0.055 (0.10%)

TODAY'S FREE FLY STORIES

VIX

Volatility Index S&P 500 Options

16:20
04/20/18
04/20
16:20
04/20/18
16:20
Options
Closing CBOE SPX and VIX Index summary for April 20th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRK

Park National

$105.24

-0.49 (-0.46%)

16:17
04/20/18
04/20
16:17
04/20/18
16:17
Hot Stocks
Park National raises quarterly dividend to 96c per share from 94c »

Park National's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRK

Park National

$105.24

-0.49 (-0.46%)

16:17
04/20/18
04/20
16:17
04/20/18
16:17
Earnings
Breaking Earnings news story on Park National »

Park National reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

16:17
04/20/18
04/20
16:17
04/20/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRMB

Trimble

$36.57

-0.16 (-0.44%)

16:16
04/20/18
04/20
16:16
04/20/18
16:16
Hot Stocks
Trimble acquires assets of FabSuite, terms not disclosed »

Trimble announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
04/20/18
04/20
16:16
04/20/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$111.69

0.56 (0.50%)

16:15
04/20/18
04/20
16:15
04/20/18
16:15
Hot Stocks
Celanese names Benita Casey chief accounting officer »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 30

    May

SSW

Seaspan

$7.75

0.725 (10.32%)

16:15
04/20/18
04/20
16:15
04/20/18
16:15
Hot Stocks
Seaspan COO/General Counsel Mark Chu steps down »

Seaspan Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

HON

Honeywell

$150.52

2.165 (1.46%)

, GE

General Electric

$14.54

0.55 (3.93%)

16:15
04/20/18
04/20
16:15
04/20/18
16:15
General news
On The Fly: Top stock stories for Friday »

Stocks opened little…

HON

Honeywell

$150.52

2.165 (1.46%)

GE

General Electric

$14.54

0.55 (3.93%)

AAPL

Apple

$165.71

-7.08 (-4.10%)

WFC

Wells Fargo

$52.57

1.02 (1.98%)

AGN

Allergan

$158.48

-0.11 (-0.07%)

WAB

Wabtec

$87.54

3.8 (4.54%)

SHPG

Shire

$164.43

3.63 (2.26%)

TKPYY

Takeda Pharmaceutical

MAT

Mattel

$12.95

-0.49 (-3.65%)

TSM

TSMC

$38.96

-0.57 (-1.44%)

PF

Pinnacle Foods

$60.58

5.38 (9.75%)

LLNW

Limelight Networks

$4.99

0.89 (21.71%)

TRU

TransUnion

$66.84

6.33 (10.46%)

CHD

Church & Dwight

$45.90

-2.82 (-5.79%)

CLW

Clearwater Paper

$26.90

-13.55 (-33.50%)

SKX

Skechers

$30.70

-11.3903 (-27.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 20

    Apr

  • 20

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

  • 27

    Apr

  • 30

    Apr

  • 01

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 08

    May

  • 15

    May

  • 23

    May

  • 30

    May

  • 12

    Jun

  • 25

    Jun

  • 21

    Dec

WASH

Washington Trust

$56.35

0.45 (0.81%)

16:08
04/20/18
04/20
16:08
04/20/18
16:08
Earnings
Washington Trust reports Q1 adjusted EPS 93c, consensus 87c »

Q1 Returns on average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 14

    May

INVE

Identiv

$3.54

0.03 (0.85%)

16:05
04/20/18
04/20
16:05
04/20/18
16:05
Syndicate
Breaking Syndicate news story on Identiv »

Identiv files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

AA

Alcoa

$59.78

-0.47 (-0.78%)

, AAL

American Airlines

$46.58

-0.3 (-0.64%)

16:02
04/20/18
04/20
16:02
04/20/18
16:02
Periodicals
Breaking Periodicals news story on Alcoa, American Airlines, Alaska Air, Boeing, Delta Air Lines, General Electric, Southwest, United Continental, JetBlue »

FAA to prepare emergency…

AA

Alcoa

$59.78

-0.47 (-0.78%)

AAL

American Airlines

$46.58

-0.3 (-0.64%)

ALK

Alaska Air

$65.41

-0.14 (-0.21%)

BA

Boeing

$337.30

-3.25 (-0.95%)

DAL

Delta Air Lines

$55.33

0.27 (0.49%)

GE

General Electric

$14.65

0.655 (4.68%)

LUV

Southwest

$54.64

-0.14 (-0.26%)

UAL

United Continental

$71.73

1.485 (2.11%)

JBLU

JetBlue

$19.83

0.17 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 23

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 09

    May

  • 10

    May

  • 29

    May

  • 30

    May

  • 26

    Jun

  • 29

    Jun

PSX

Phillips 66

$110.85

0.23 (0.21%)

15:55
04/20/18
04/20
15:55
04/20/18
15:55
Options
Phillips 66 put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

ULTI

Ultimate Software

$244.01

-4.76 (-1.91%)

15:51
04/20/18
04/20
15:51
04/20/18
15:51
Hot Stocks
Ultimate Software announces SMS Equipment to use its reporting product »

Ultimate Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 12

    Jun

C

Citi

$69.85

-0.43 (-0.61%)

, USB

U.S. Bancorp

$50.24

-0.45 (-0.89%)

15:49
04/20/18
04/20
15:49
04/20/18
15:49
Periodicals
Big U.S. banks race to launch mortgage apps as home lending slows, Reuters says »

Large U.S. banks are…

C

Citi

$69.85

-0.43 (-0.61%)

USB

U.S. Bancorp

$50.24

-0.45 (-0.89%)

JPM

JPMorgan

$111.07

-0.66 (-0.59%)

BAC

Bank of America

$30.19

-0.015 (-0.05%)

GS

Goldman Sachs

$251.52

-2.67 (-1.05%)

WFC

Wells Fargo

$52.49

0.94 (1.82%)

MS

Morgan Stanley

$54.11

-0.58 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

  • 02

    May

  • 15

    May

  • 16

    May

  • 23

    May

  • 30

    May

  • 06

    Jun

  • 13

    Jul

  • 12

    Oct

T

AT&T

$34.67

-0.15 (-0.43%)

, VZ

Verizon

$48.01

-0.43 (-0.89%)

15:46
04/20/18
04/20
15:46
04/20/18
15:46
Periodicals
U.S. investigating wireless collusion claim against AT&T, Verizon, NY Times says »

The U.S. Department of…

T

AT&T

$34.67

-0.15 (-0.43%)

VZ

Verizon

$48.01

-0.43 (-0.89%)

S

Sprint

$6.00

0.045 (0.76%)

TMUS

T-Mobile

$63.28

0.02 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 09

    May

HPE

HP Enterprise

$17.23

-0.19 (-1.09%)

15:45
04/20/18
04/20
15:45
04/20/18
15:45
Options
Hewlett Packard Enterprise call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 11

    Jun

T

AT&T

$34.64

-0.18 (-0.52%)

, VZ

Verizon

$47.99

-0.45 (-0.93%)

15:42
04/20/18
04/20
15:42
04/20/18
15:42
Periodicals
Breaking Periodicals news story on AT&T, Verizon, Sprint, T-Mobile »

U.S. investigating…

T

AT&T

$34.64

-0.18 (-0.52%)

VZ

Verizon

$47.99

-0.45 (-0.93%)

S

Sprint

$6.00

0.045 (0.76%)

TMUS

T-Mobile

$63.27

0.01 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 09

    May

ALXN

Alexion

$106.59

-5.15 (-4.61%)

15:36
04/20/18
04/20
15:36
04/20/18
15:36
Hot Stocks
Alexion says no licence of Soliris was requested or granted in Brazil »

Recent media reports have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

SYNT

Syntel

$28.04

0.19 (0.68%)

15:35
04/20/18
04/20
15:35
04/20/18
15:35
Recommendations
Syntel analyst commentary  »

Syntel's rest of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

TRUP

Trupanion

$27.51

-1.42 (-4.91%)

15:35
04/20/18
04/20
15:35
04/20/18
15:35
Periodicals
Trupanion cost saving sharing may violate state laws, Capitol Forum says »

Insurance experts and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 10

    May

BURL

Burlington Stores

$132.82

-3.36 (-2.47%)

15:30
04/20/18
04/20
15:30
04/20/18
15:30
Options
Bullish option play in Burlington Stores as shares slump »

Bullish option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIA

Viacom

$35.35

-0.25 (-0.70%)

, FOXA

21st Century Fox

$36.69

-0.51 (-1.37%)

15:29
04/20/18
04/20
15:29
04/20/18
15:29
Hot Stocks
Box Office Battle: 'A Quiet Place' expected to creep back into top spot »

Expected to return to the…

VIA

Viacom

$35.35

-0.25 (-0.70%)

FOXA

21st Century Fox

$36.69

-0.51 (-1.37%)

LGF.B

Lionsgate

$23.89

-0.55 (-2.25%)

VIAB

Viacom

$30.77

0.02 (0.07%)

CMCSA

Comcast

$33.14

-0.35 (-1.05%)

CMCSK

Comcast

LGF.A

Lionsgate

$25.72

-0.48 (-1.83%)

TWX

Time Warner

$95.98

-0.59 (-0.61%)

DIS

Disney

$100.01

-0.87 (-0.86%)

SNE

Sony

$49.70

-0.03 (-0.06%)

FOX

21st Century Fox

$36.12

-0.55 (-1.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 08

    May

  • 09

    May

  • 09

    May

ALXN

Alexion

$106.37

-5.37 (-4.81%)

15:28
04/20/18
04/20
15:28
04/20/18
15:28
Recommendations
Alexion analyst commentary  »

Alexion shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

ANF

Abercrombie & Fitch

$26.36

-1.08 (-3.94%)

15:25
04/20/18
04/20
15:25
04/20/18
15:25
Options
Abercrombie & Fitch call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 12

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.